Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a report issued on Thursday, TipRanks reports.
Several other analysts have also recently issued reports on CRSP. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Goldman Sachs Group upped their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. BidaskClub cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 23rd. Canaccord Genuity upped their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research note on Wednesday, November 20th. Finally, ValuEngine cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $75.95.
Shares of CRSP opened at $52.42 on Thursday. The company has a market capitalization of $2.99 billion, a P/E ratio of -113.96 and a beta of 3.20. Crispr Therapeutics has a one year low of $29.34 and a one year high of $74.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a 50-day moving average price of $61.34 and a 200 day moving average price of $52.68.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. As a group, equities research analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. Insiders have sold a total of 48,618 shares of company stock worth $3,230,760 over the last quarter. Insiders own 21.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in CRSP. NEXT Financial Group Inc raised its position in shares of Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares during the period. Coastal Investment Advisors Inc. acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter worth approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in shares of Crispr Therapeutics during the 4th quarter worth approximately $26,000. Webster Bank N. A. acquired a new stake in shares of Crispr Therapeutics during the 4th quarter worth approximately $26,000. Finally, US Bancorp DE raised its position in shares of Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares during the period. Institutional investors and hedge funds own 49.84% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.